These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33881797)

  • 21. Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes.
    Yale JF; Aroda VR; Charbonnel B; Sinclair AJ; Trescoli C; Cahn A; Bigot G; Merino-Trigo A; Brulle-Wohlhueter C; Bolli GB; Ritzel R
    Diabetes Metab; 2020 Apr; 46(2):110-118. PubMed ID: 30366067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
    Bolli GB; Riddle MC; Bergenstal RM; Ziemen M; Sestakauskas K; Goyeau H; Home PD;
    Diabetes Obes Metab; 2015 Apr; 17(4):386-94. PubMed ID: 25641260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating the clinical effectiveness and safety of insulin glargine 300 U/mL in individuals with type 2 diabetes uncontrolled on basal insulin: A real-world evidence study from Saudi Arabia (EVOLUTION).
    Al Malki F; El Damanhoury B; Othman A; Alghamdi Z; AlQahtani M; Madgy A; Chouikrat Z
    Diabetes Obes Metab; 2023 Oct; 25(10):2869-2877. PubMed ID: 37485767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study.
    Escalada J; Bonnet F; Wu J; Bonnemaire M; Gupta S; Cambron-Mellott JM; Nicholls C; Müller-Wieland D
    Adv Ther; 2020 Sep; 37(9):3863-3877. PubMed ID: 32681460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin.
    Zhou FL; Ye F; Berhanu P; Gupta VE; Gupta RA; Sung J; Westerbacka J; Bailey TS; Blonde L
    Diabetes Obes Metab; 2018 May; 20(5):1293-1297. PubMed ID: 29272064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The economic value of insulin glargine 300 U/mL (Gla-300) in people ≥18 years of age with type 2 diabetes mellitus: a value-based economic model from a U.S. payer perspective.
    Ponomareva E; Schmerold L; Sss S; Preblick R; Park S; Wilson L; Revel A
    J Med Econ; 2023; 26(1):1469-1478. PubMed ID: 37916295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
    Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J
    Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta-analysis of 6-month phase 3 clinical trials.
    Danne T; Matsuhisa M; Sussebach C; Goyeau H; Lauand F; Niemoeller E; Bolli GB
    Diabetes Obes Metab; 2020 Oct; 22(10):1880-1885. PubMed ID: 32515543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL.
    Philis-Tsimikas A; Lane W; Pedersen-Bjergaard U; Wysham C; Bardtrum L; Harring S; Heller S
    Diabetes Obes Metab; 2020 May; 22(5):779-787. PubMed ID: 31903697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study.
    Wolnik B; Wiza D; Szczepanik T; Syta A; Klupa T
    J Diabetes Res; 2020; 2020():8751348. PubMed ID: 32337298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative clinical efficacy and safety of insulin glargine 300 U/ml (Toujeo) versus insulin glargine 100 U/ml in type 2 diabetes and type 1 diabetes: A systematic literature review and meta-analysis.
    Joshi SR; Singh G; Marwah A; Mittra S; Suvarna VR; Athalye SN
    Diabetes Obes Metab; 2023 Jun; 25(6):1589-1606. PubMed ID: 36748186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin-naïve people with type 2 diabetes: The EDITION AP randomized controlled trial.
    Ji L; Kang ES; Dong X; Li L; Yuan G; Shang S; Niemoeller E;
    Diabetes Obes Metab; 2020 Apr; 22(4):612-621. PubMed ID: 31797549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes.
    Ritzel R; Roussel R; Giaccari A; Vora J; Brulle-Wohlhueter C; Yki-Järvinen H
    Diabetes Obes Metab; 2018 Mar; 20(3):541-548. PubMed ID: 28862801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C-peptide levels in insulin-naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial.
    Bolli GB; Landgraf W; Bosnyak Z; Melas-Melt L; Home PD
    Diabetes Obes Metab; 2020 Sep; 22(9):1664-1669. PubMed ID: 32314521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin Glargine 300 U/mL Therapy in Children and Adolescents with Type 1 Diabetes.
    Maffeis C; Rabbone I
    Paediatr Drugs; 2022 Sep; 24(5):499-512. PubMed ID: 35881330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes.
    Ritzel R; Roussel R; Bolli GB; Vinet L; Brulle-Wohlhueter C; Glezer S; Yki-Järvinen H
    Diabetes Obes Metab; 2015 Sep; 17(9):859-67. PubMed ID: 25929311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Much ado about nothing? A real-world study of patients with type 2 diabetes switching Basal insulin analogs.
    Wei W; Zhou S; Miao R; Pan C; Xie L; Baser O; Gill J
    Adv Ther; 2014 May; 31(5):539-60. PubMed ID: 24831915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study.
    Pettus J; Roussel R; Liz Zhou F; Bosnyak Z; Westerbacka J; Berria R; Jimenez J; Eliasson B; Hramiak I; Bailey T; Meneghini L
    Diabetes Ther; 2019 Apr; 10(2):617-633. PubMed ID: 30767173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4).
    Home PD; Bergenstal RM; Bolli GB; Ziemen M; Rojeski M; Espinasse M; Riddle MC
    Diabetes Obes Metab; 2018 Jan; 20(1):121-128. PubMed ID: 28661585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutically interchangeable? A study of real-world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data.
    Levin P; Wei W; Miao R; Ye F; Xie L; Baser O; Gill J
    Diabetes Obes Metab; 2015 Mar; 17(3):245-53. PubMed ID: 25359227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.